The American Biotechnology Investment Agency Arch Venture Partners announced the completion of the $ 3 billion Arch Venture Fund XIII fundraising to support the establishment and development of early biotechnology companies.The thirteenth fund was established after the twelfth fund announced by US $ 2.975 billion announced in June 2022.Robert Nelsen, co -founder and managing director of Arch, said: "After 38 years of development, Arch's investment philosophy is consistent: we bet on the great scientific and excellent team to establish a breakthrough company.Smart and data -driven biology new opinions will help build a more precise, therapeutic and fair medical care system.The top forward -looking trend of scientific research and development and the individual in promoting the real breakthrough scientific assumption has a long history.

In February this year, Arch announced the completion of the 13 billion US dollars of the 13th new fund raising, and it was less than two years since the company's largest $ 3 billion of financing was less than two years.So far, the thirteenth fund has invested in a number of biotechnology companies including XAIRA Therapeutics, Metsera, ARSENALBIO, and Mirador Therapeutics.Among them, Xaira Therapeutics received a huge amount of financing of US $ 1 billion from the fund XIII in April.This is also the highest amount of financing in the biomedical field this year.When artificial intelligence, as a transformative technology, Arch believes that the field of imagination of the next gene Tyk or regenerative element, XAIRA is highly hoped.Jaipur Wealth Management

Xaira was founded in May 2023 and is still stealth.XAIRA was co -founded by Bob Nelsen and Foresite Labs from the two outstanding venture capital experts in the field of biotechnology.Carry out clinical trials.Drug research and development is a failed job. Through the new method of generating AI, such as designing complex molecules and finding new targets from the beginning, it can shorten the time for several months or even years.In order to better understand biology and find new drug targets, XAIRA introduced teams and technologies from gene sequencing giant Illumina and the interrapeutics of biotechnology startups, focusing on protein groups, that is, how protein is healthy and diseasedChanges in.

With the completion of the 13th fund fundraising, as of now, Arch has raised a total of 13 funds, with a total management scale of $ 12.3 billion.From the perspective of ARCH's investment projects and the focus of the new fund, Arch is very optimistic about the future potential of AI pharmaceuticals, and focuses on a group of AI pharmaceutical companies.In addition to XAIRA, which set a record for biomedical financing this year, Arch also invested several AI+new drug research and development unicorn.For example, INSITRO, a AI Pharmaceutical Star Enterprise, and Daphne Koller, the founder of the company is the artificial intelligence genius female scientist Daphne Koller (Daphne Kohler). It has already raised over $ 600 million. Arch is one of the founders of this company and participated in all of all the so far.Financing.

In addition, AI+protein therapy with a cumulative financing of over 700 million US dollars has initially created Generate: Biomedicines, and there is ARCH support behind it.Founded in 2018, GENATE aims to understand the relationship between protein sequences, structures and functions through artificial intelligence technology, thereby designing the new protein that has never been seen from the beginning.Generate's proprietary genera (General Platform) can generate, build, measure, and learn in a continuous cycle, which can greatly increase the recognition and verification speed of targets and treatment drugs.This will increase the specificity of the protein participation in targets and reduce the time and costs of identification and development of clinical candidate therapy.At present, ARCH has invested funds to nearly 10 AI pharmaceutical companies, including Dewpoint Therapeutics (AI+Bioccoencies); ERASCA (AI+Cancer Precision Medicine); Neumora therapeutics (AI+brain science), Vilya (AI+large ring peptide molecules), and, and,,Lifemine therapeutics (AI+fungal drug discovery), etcVaranasi Stock. Among them, EraSca and Neumora therapeutics have successfully IPO, which has been recognized by the capital market.

As a well -known early investment institution in the field of life sciences in the United States, Arch has always been unhappy with investing in top scientists and technology platforms.Arch Venture was founded in 1986. It was established at the University of Chicago by Steven Lazarus and Robert Nelson, Keith Crandell, and Clint Bybee, and released the first fund Arch Venture Fund I in 1989. The fund size is 9 million US dollars.The fund was originally positioned to assist the University of Chicago for the transformation of scientific and technological achievementsGuoabong Stock. Four of the 12 startups they invested in them achieved IPOs and 4 were acquired.

In 1992, the founding team was independent of the University of Chicago and established the market -oriented fund management subject Arch Venture Partners, and completed the release of the second fund the following year.This fund is very successful and invest in 22 companies, 6 of which continue the company's investment.It was during this period that they gradually realized that Arch was becoming a seed fund and early venture capital funds.At the same time, this fund also invested in its own company in the later period, which not only reduces the overall risk level of the investment portfolio, but also shorten the time to recover the investment.

The success of the second fund also brought ARCH's fame, making its investment scope from laboratory to the company, opening the road to investing in new technology startups.Since then, ARCH has raised a new phase of fund for three years.There have been industry analysis and summarizing ARCH's investment style. First, it is biased towards platform -type technology and can be used in universal technologies in multiple fields.The second is to incubate the company and participate in the post -investment.The third is to make progress and dare to take risks.Jaipur Stock

This investment style can be seen from its representative investment projects.ARCH is the original investor of DNA sequencing giant Illumina. Over the years, many leading companies in the field of biotechnology have been deployed, including RNA drug leader Alnylam, cell therapy head company Juno, autoimmune drug development company, Receptos, antibody drug company VIR, and gene editingHead -headed companies, BEAM and DNA synthetic leader Twist, etc., and have acquired global leading biotechnology companies such as Cancer Early Sieve Grail and Chemical protein leader Vividion.Although ARCH also has a large number of medium and late project investment, compared with other funds in the early investment field, ARCH is more advanced.Arch's investment strategy is to evaluate opportunities and science first, and then consider how to create a company.The maturity of technology and the development of the industry are different, and the company's establishment time and time and energy that need to be invested are also different.

Many of the newly invested in Archs started from the academic circle.ARCH allows scientists to serve as management positions, and at the same time develop new types of technology. They believe that having knowledge of the pharmaceutical industry, and at the same time work in the academic circle, has great advantages.Arch's judgment criteria are mainly novel technology, target market size, and team strength.Through early investment, ARCH will continue to increase investment after assisting the reliability of the founding team's verification mechanism and the adults of the target to help the company complete the team building and pipeline design until the company is pushed to the public capital market.

For the lack of CEOs that professors often encounter, ARCH chooses to solve the in -depth linkage with the industry.Arch usually invites senior industrial experts in different directions to become Arch's Venture Partner or consultant to participate in the preparation and project evaluation of startups.When the project develops to the right time, the willing expert may change the status to the CEO to assist the project to land.Investment in the field of pharmaceuticals often shows the significant characteristics of high risk and high returns, especially for investment in early projects.ARCH has broadcasted the market for scientific research through unique judgment standards and investment concepts.In the entire venture capital industry, this method also affects far -reaching.

In addition to Arch, many medical venture capitals have successfully received new fundraising this year.In July, Flagship Pioneering raised up to $ 3.6 billion in funds, and is expected to support 25 companies.In June, ForeSite Capital disclosed $ 900 million in funds.In addition, Sands Capital raised $ 555 million in May, and in February, SCION LIFE Sciences raised $ 310 million, and TCGX announced a new funds of $ 1 billion in January.

At the same time, investment in the domestic biomedical field is gradually "getting out of the trough."Among them, in January, Hui Each Capital officially announced the completion of the final account of the new RMB Venture Capital Fund with a total scale of 1.5 billion yuan; March, Sequoia India successfully raised 18 billion yuan funds, which is also the risk of India in the past year.The biggest fundraising of investment institutions; June, Decheng Capital disclosed the fifth phase of the fund to raise $ 700 million; in July, Longriver Jiangyuan Investment announced that the first phase of the US dollar fund was raised, with a scale of nearly 400 million US dollars,etc.Signs of recovery seem to be manifested, and even A shares have risen.If this recovery momentum can continue and get more response, it may not be the dawn of the economic winter.